PROT# TOG201: A Phase II Study of Tesetaxel Administered at a Flat Dose Once Every 21 Days as Second-Line Therapy to Subjects with Advanced Gastric Cancer

Project: Research project

Project Details

StatusFinished
Effective start/end date3/25/10 → 12/25/17

Funding

  • Genta Incorporated (TOG201)